(1) Maternal alloimmunization against fetal platelets can cause fetal and neonatal thrombocytopenia (NAIT).
(2) Improvements in antenatal diagnosis and in utero therapy facilitate appropriate management of pregnancy at risk for NAIT.
(3) There is evidence that in certain cases antibodies against blood group antigens A or B may cause NAIT.
(4) Recent evidence that NAIT is more common than has previously been recognised, a better understanding of the molecular basis of platelet serology and advances in technology, which have made it possible to take blood samples from fetuses and transfuse them in utero, have all contributed to a growing interest in this condition.
(5) Neonatal alloimmune thrombocytopenia (NAIT) is caused by platelet antigen incompatibility between the mother and fetus.
(6) Neonatal alloimmune thrombocytopenia (NAIT) occurs when maternal alloantibodies to antigens present on fetal platelets cause their immune destruction resulting in thrombocytopenia in the newborn infant or fetus.
(7) Neonatal alloimmune thrombocytopenia (NAIT) is due to fetomaternal incompatibility for platelet specific antigens, most frequently HPA-1a (PLA1) and HPA-5b (BRa).
(8) A 31 year old woman was assessed following delivery of her second child affected by neonatal alloimmune thrombocytopenia (NAIT).
(9) An immune response to human platelet antigens (HPA), as in neonatal alloimmune thrombocytopenia (NAIT) and post-transfusion purpura (PTP), is the exception rather than the rule and evidence is accumulating for the importance of human leucocyte antigen (HLA) class II restriction in this situation.
(10) This report of an unaffected pregnancy in a woman with a history of previous pregnancies complicated by NAIT illustrates the role of paternal and fetal platelet phenotyping in managing existing pregnancies at risk of NAIT.
(11) The sera of 219 Zwa-positive mothers who gave birth to children with clinically suspected neonatal alloimmune thrombocytopenia (NAIT) were tested for platelet-reactive antibodies using the platelet adhesion immunofluorescence test and a glycoprotein-specific immunoassay (MAIPA).
(12) Because there is high risk that subsequent pregnancies might be also affected by NAIT, the mothers of a previously affected child should be managed similarly to the HPA-1b mothers (PIA2, Zwb).
(13) Platelet specific alloantibodies cause neonatal alloimmune thrombocytopenia (NAIT), posttransfusion purpura (PTP) and may be found in patients who are refractory to HLA-matched platelet transfusion.
(14) In accordance with established criteria, the Sra antigen represents the first example of a "private" platelet alloantigen that bears significance in rare instances of NAIT.
(15) We report our experience with the serological diagnosis of 14 NAIT cases using new performing techniques such as western blotting (WB) and MAIPA (monoclonal antibody specific immobilization of platelet antigens).
(16) This is a report of 39 cases of NAIT involving the HPA-5b antigen.
(17) Bra antibodies were from mothers of children with neonatal alloimmune thrombocytopenia (NAIT), and anti-Brb was found in the serum of a polytransfused patient.
(18) NAIT is mainly due to alloimmunization; the frequency varying among ethnic groups.
(19) Immunization against these alloantigens is implicated in NAIT and poly-transfused patients.
(20) In the serum of a mother who gave birth to a child with the typical clinical picture of NAIT we found an antibody directed against the new platelet antigen Sra.
Naitp
Definition:
Example Sentences:
(1) Neonatal alloimmune thrombocytopenic purpura (NAITP) is induced by maternal antibodies to fetal platelet alloantigens.
(2) They review the platelet antigen systems involved in NAITP and raise the problem of its present antenatal and postnatal management.
(3) This antigen is considered to be a product of an allele of the Yuk gene, another allele of which codes for Yuka which was involved in 2 cases of NAITP.
(4) anti-HLA-A24+B51 and anti-HLA-Bw61+Cw3, respectively, were detected in the mother's sera, which reacted to each patient's lymphocytes and were presumed to have been contribute to NAITP.
(5) Antibodies to the platelet HPA-1a antigen can elicit in the newborn a condition known as neonatal alloimmune thrombocytopenic purpura (NAITP).
(6) The case report emphasises that in patients with NAITP intracranial haemorrhage may occur in utero and during the perinatal period as well.
(7) Furthermore, in a review from the currently available literature the following items will be discussed: 1) human platelet antigens involved in NAITP, 2) clinical aspects and prognosis of NAITP, 3) immunological diagnosis of NAITP, and 4) prevention and treatment of the disease.
(8) We propose further study to determine if this is specific for the antepartum diagnosis of NAITP.
(9) Here reported are two cases with neonatal alloimmune thrombocytopenia (NAITP).
(10) However, the strongest association both in mothers of NAITP patients and in PTP patients was observed with the supertypic DRw52 antigen.
(11) On the other hand, some NAITP cases may have been overlooked because of their mildness.
(12) The only mother who was delivered of a child with clinical NAITP was the woman with anti-Zwa(PIA1) in serum.
(13) Sensitive assays of maternal platelet alloantibody are now available, but they lack specificity for NAITP affecting the current gestation.
(14) The authors report a case of two siblings who developed a neonatal alloimmune thrombocytopenia (NAITP) due to Bak-System incompatibility.
(15) We report a new platelet antigen (Yukb) involved in a case of neonatal alloimmune thrombocytopenia (NAITP).
(16) We demonstrate the sonographic and computer-tomographic findings in a newborn with neonatal alloimmune thrombocytopenia (NAITP).
(17) The strong association between HLA-DR3 and Zwa alloimmunization in Zwa-negative mothers, resulting in the production of anti-Zwa antibodies and ultimately in neonatal alloimmune thrombocytopenic purpura (NAITP) in the newborn, could be confirmed.
(18) We reviewed 58 literature reports of neonatal alloimmune thrombocytopenic purpura (NAITP).